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Objectives: The aim of the study was to investigate the dispensing patterns of prescription-only antiobesity preparations in 
South Africa (classified as Anatomical Therapeutic Chemical (ATC) group A08).
Design: Retrospective, cross-sectional drug utilisation study using electronic dispensing records.
Setting: Private sector community or retail pharmacies in South Africa.
Subjects: Patients who received one or more antiobesity medications in ATC group A08 in 2013.
Outcome measures: Number of patients by age and gender, prescribing frequency and cost of antiobesity prescriptions, and 
trends observed.
Results: A total of 27 703 patients were prescribed 52 555 products for antiobesity medication during 2013. The average age 
of patients was 41.71 (SD = 11.37) years, with male patients older than female patients (46.09 and 40.02 years, respectively). 
More females (72.19%) were dispensed antiobesity products, and females received their prescriptions at a younger average 
age than male patients. Five active ingredients were dispensed. Phentermine was prescribed the most, accounting for 92.44% 
of all the antiobesity prescriptions, followed by orlistat (6.08%), phendimetrazine (1.36%), D-norpseudoephedrine (0.06%) and 
diethylpropion (0.05%). Most patients (79.44%) received only short-term therapy (one or two prescriptions for an antiobesity 
product during the year). A small percentage (0.30%) of young patients (18 years and younger) received antiobesity products, 
despite the fact that the safety of these products in children has not been proven.
Conclusions: Most antiobesity preparations were prescribed to females. Phentermine was the most commonly dispensed active 
ingredient, followed by orlistat. Further studies on patient outcomes and the cost-effectiveness of these products should be 
conducted. 
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Introduction
Obesity is a major global public health problem.1,2 It is one of the 
most serious and prevalent non-communicable diseases of the 
21st century.3 The obesity epidemic has been growing in 
developed nations for decades.1 Growing affluence has been 
accompanied by the emergence of overweight and obesity, to 
the extent that the proportion of underweight and overweight 
persons has inverted.4 The worldwide burden of obesity is 
estimated at 1.5 billion overweight persons and 500 million 
obese persons.5 Obesity-associated comorbidities, including 
major diseases such as cardiovascular disease, diabetes (type 2) 
and various cancers, are well-known.2 In June 2013, the American 
Medical Association officially recognised obesity as a chronic 
medical disease state.3
A study in the Lancet6 reported that the worldwide proportion of 
adults with a body-mass index (BMI) of 25  kg/m2 or greater 
increased between 1980 and 2013 from 28.8% to 36.9% in men, 
and from 29.8% to 38.0% in women. Prevalence has also 
increased substantially in children and adolescents in developed 
countries, as well as in developing countries.6 The result of this is 
an increase in the prevalence of chronic diseases associated with 
obesity in younger people.
Sub-Saharan Africa was minimally affected by the obesity 
epidemic due to under-nutrition and a major burden of HIV and 
tuberculosis until recently.2,7 However, the obesity epidemic has 
also spread to developing countries, with obesity and its 
association with co-morbidities in Africa on the rise.8 Obesity is 
now regarded as a major risk factor for emerging non-
communicable diseases in middle income countries, including 
South Africa.2
South Africa is undergoing a rapid epidemiological transition 
and has the highest prevalence of obesity in sub-Saharan Africa.7 
Although different studies and surveys report different numbers, 
the reported prevalence for overweight and obesity in South 
Africa is alarming. The Lancet study found that 70% of South 
African women are overweight and 42% are obese.6 The study 
was conducted by the Institute for Health Metrics and Evaluation 
at the University of Washington, and was a first-of-its-kind 
analysis of data between 1980 and 2013 from 188 countries.6 
Socio-cultural, environmental and behavioural factors, including 
socio-economic status, are likely to explain the high prevalence 
of obesity in South Africa.7,9
Lifestyle modifications are the first-line of treatment for obesity, 
followed by pharmacotherapy.1 Several prescription medications 
are approved to treat obesity, yet little is known about their 
prescribing and use in South Africa. A study10 conducted on a 
small patient sample reported on the prescribing of appetite 
suppressants in 2010 and 2011, but no studies on larger South 
African patient populations could be found.
There are two classes of antiobesity products available in South 
Africa, namely centrally-acting and peripherally-acting 
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antiobesity preparations. Centrally-acting antiobesity products 
include diethylpropion (amfepramone), phentermine and 
phendimetrazine. These active ingredients are sympathomimetics 
with central nervous system (CNS) stimulant properties similar to 
dexamphetamine, and they have significant abuse potential.11 
Cathine (D-norpseudoephedrine) is also a sympathomimetic 
compound with CNS stimulant properties. It is used as an adjunct 
to lifestyle modification, and it also has significant abuse 
potential.11 These compounds are Schedule 6 (except for 
phentermine which is a Schedule 5 medicine). Peripherally-acting 
antiobesity products include only one product, namely orlistat, 
which is a Schedule 3 product and it is therefore less strictly 
controlled. Orlistat is indicated for the management of obesity in 
conjunction with a hypocaloric diet in patients with BMI ≥ 30 kg/
m2, or ≥ 27 kg/m2 with co-morbidities, only if 2.5 kg has been lost 
on diet alone over a 4-week period.11 Orlistat is a gastrointestinal 
lipase inhibitor which lowers the absorption of dietary fat by 
approximately 30%.11 However, severe gastrointestinal adverse 
events due to fat malabsorption may occur.11 These antiobesity 
preparations should not be combined, and their long-term use is 
not advised.11 Their duration of efficacy is limited, and differs for 
each individual agent.11 There may be cross-tolerance to other 
agents.11 There are limited studies showing safety and efficacy of 
the noradrenergics beyond 6 months.11
Studies on the prescribing patterns of antiobesity products in 
South Africa are limited. In addition, there are no safety and 
efficacy data for the use of these agents in children. The aim of 
the study was therefore to investigate the dispensing patterns of 
antiobesity prescriptions in Anatomical Therapeutic Chemical 
(ATC) group A08 using electronic dispensing records of 
community pharmacies in South Africa.
Methodology
A retrospective, cross-sectional drug utilisation study was 
conducted on a private sector community (or retail) pharmacy 
dispensing database of approximately 54 million records 
dispensed by 327 community pharmacies in South Africa in 2013. 
A community pharmacy refers to pharmacies from which some, 
or all, of the services as prescribed in terms of regulation 18 of the 
Regulations Relating to the Practice of Pharmacy in the Pharmacy 
Act are provided to the general public or any defined group of 
the general public, but excludes an institutional pharmacy (for 
example, a hospital pharmacy). According to the South African 
Pharmacy Council, there are 3  082 registered community 
pharmacies in South Africa.12 The data therefore included 
approximately 10% of all community pharmacy dispensing 
records in the country in 2013. The database consisted of 
dispensing information from pharmacies in all nine provinces of 
South Africa, and included dispensing records from all the 
participating pharmacies. Prescriptions included both medical 
aid claims and prescriptions that were paid for at the pharmacies’ 
dispensaries. Most of the prescriptions were classified under 
private purchases (63.89%) since not all medical schemes 
reimburse antiobesity preparations, while the rest (36.11%) were 
claimed under a variety of medical aid scheme options.
The ATC Classification System,13 MIMS (Monthly Index of Medical 
Specialities)14 and the South African Medicines Formulary11 were 
used to classify medicines. All products in ATC subgroup A08 
(antiobesity preparations, excluding diet products) were 
extracted and analysed. The ATC Classification system is 
recommended by the World Health Organisation as the standard 
medicine classification system for drug utilisation studies in the 
world in order to enable comparative studies to be conducted.
Each medication record contained information on the age and 
gender of the patient, with a unique number to identify each 
patient, the date of the prescription, detailed information on 
the dispensed drug (name, package size, formulation, strength 
and quantity) and gross sales value. Dosage instructions were 
available in the database, but were not consistent in how they 
were recorded and were therefore not analysed in detail. At 
the time of the study, one Euro (€1.00) was equal to R12.86 
(South African Rand), one US Dollar ($1.00) was equal to R9.88 
and one British Pound (£1.00) was equal to R15.03 (30 June 
2013).
Microsoft Access® and Excel® were used to analyse the data. 
Descriptive statistics were calculated. Results were described 
according to means and standard deviations for numerical data, 
and frequencies and percentages for categorical data. The 
Pearson’s chi-squared test was used to determine statistical 
significant differences between sub-groups. A p-value < 0.05 was 
considered statistically significant.
Ethical approval to conduct studies on prescription databases 
was obtained from the Research Ethics Committee (Human) of 
the university (ethics clearance number: H08-HEA-PHA-005). The 
dispensing records in the database were de-identified, meaning 
that no patient or prescriber could be identified. A patient 
identifier was added to enable the researchers to uniquely 
identify each patient in terms of age and gender, and to calculate 
the number and spectrum of products that a specific patient 
received, but it was a neutral code and not an identity or medical 
aid number.
Results
Demographic information of patients
A total of 27  703 patients were dispensed one or more 
prescriptions in ATC group A08. The majority of the patients 
(72.19%; n = 20 000) were females. The average age of patients 
was 41.71 (SD = 11.37) years. The average age of female patients 
was 40.02 (11.01) years, and male patients was 46.09 (11.13) 
years. The percentage gender distribution of the 27 703 patients 
according to age groups is given in Figure 1. The chi-square test 
was used to detect differences between female and male patients 
in the different age groups (χ2  = 2844.8; d.f.  = 3; p  < 0.0001). 
Differences were observed, with proportionally more female 
patients in the younger adult age group (19 to 34  years), and 
more male patients in the older age groups (35 years and older).
Figure 1. Percentage gender distribition of patients according to age 
groups (N = 27 703)*.
*χ2 = 2844.8; d.f. = 3; p < 0.0001.
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General dispensing trends
The 27 703 patients were dispensed a total of 52 555 prescriptions 
for antiobesity products at a total cost of R12 887 891.55 during 
2013. A prescription is, for the purposes of this study, defined as 
one issue of a specific medicine to a patient and can consist of a 
variable number of tablets or capsules. For chronic conditions, 
prescriptions are issued for a month’s supply. In this study, 
93.66% of prescriptions were for 30 tablets or capsules or less 
(92.86% of prescriptions contained exactly 30 tablets or 
capsules). Most patients (79.44%) received only one or two 
prescriptions for an antiobesity product during the year. Patients 
were dispensed an average of 1.90 (SD  = 1.69) prescriptions 
during the year. Female patients received an average of 1.83 
(SD = 1.57) prescriptions and male patients an average of 2.08 
(SD = 1.96) prescriptions during the 12 months.
Figure 2. Number of prescriptions dispensed according to age and gender (N = 52 555).
Figure 3. Seasonal variations in the dispensing of antiobesity prescriptions (N = 52 555).
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Diagnoses codes (ICD-10 codes)15 were included in the database, 
but they were not specific. The majority (92.37%) of prescriptions 
had a “Z” code (factors influencing health status and contact with 
health services), 3.40% had a “U” code (codes for special purposes), 
1.66% had an “E” code (endocrine, nutritional and metabolic 
diseases) and 1.30% an “R” code (symptoms, signs and abnormal 
clinical and laboratory findings, not elsewhere classified).
Prescribing frequency and cost of the different antiobesity 
prescriptions
The prescribing frequency of the different antiobesity active 
ingredients is given in Table 1. Phentermine was prescribed the 
most, accounting for 92.44% of all the antiobesity prescriptions, 
followed by orlistat (6.08%).
The average cost per antiobesity prescription in this study was 
R245.23. The highest average cost was for the branded 
phendimetrazine, at an average cost of R615.27 per prescription. 
Phendimetrazine was also the only active ingredient with a 
generic product that was prescribed (528 prescriptions were 
dispensed of the generic, compared to 189 of the branded 
product).
Dispensing patterns of antiobesity preparations to 
patients 18 years and younger
A small percentage of patients (0.30%; n = 82) were 18 years or 
younger. Of these patients, 49 were female and 33 were male. A 
total of 179 prescriptions were dispensed to them, with 130 
prescriptions for phentermine and 17 prescriptions for orlistat. 
They received an average of 1.79 (SD = 1.61) prescriptions over 
the year, with 53 of the 82 patients only receiving one product 
during the year. The youngest patient was 2 years of age.
Discussion
The majority of patients (72.19%) who were dispensed antiobesity 
medication in this study were female. The average age of patients 
was 41.71 years, with female patients younger than male patients. 
These findings were similar to those of a previous South African 
study that was conducted on a smaller database.10
Female patients received antiobesity prescriptions at a younger 
age compared to male patients. In a study conducted in Northern 
Ireland,16 multi-level logistic regression analysis was used to 
investigate factors associated with the prescription of antiobesity 
medication. They used a population primary care prescribing 
database covering approximately 1.5 million people aged 
16  years and older during 2009 and 2010. They reported that 
although 25.0% of people were obese, only 1.3% (2.1% of 
females, 0.6% of males) received antiobesity medication.16 The 
relationship between medication rates and age differed by 
gender with prescriptions higher in younger females and older 
males.16 These findings are generally in agreement with the 
results of this study.
Of the five active ingredients dispensed in this study, phentermine 
dominated prescribing (accounting for 92.44% of all prescriptions 
in ATC group A08). In the previous South African study10 
conducted on 2010 and 2011 data, most prescriptions (80.95%) 
were also for phentermine, followed by D-norpseudoephedrine 
(14.29%) and diethylpropion (4.76%). Phentermine has been 
described as an old but understudied medication,17,18 and as a 
non-addictive medication that is likely to be helpful for many 
who are already overweight.17 Phentermine has been used in the 
The maximum number of prescriptions dispensed per patient 
during the year was 26. A patient (a 56-year-old male) received 
multiple prescriptions of 14 capsules with dosage instructions to 
take either 1 or 2 capsules per day. It could therefore not be 
considered as irrational prescribing, since only a 7 or 14 day supply 
of medication was issued at a time, possibly to prevent abuse of 
the medication. The number of prescriptions dispensed according 
to age and gender is given in Figure 2. There were more female 
patients, and they were generally prescribed antiobesity 
preparations at a younger age compared to male patients.
Seasonal variations in the dispensing patterns were investigated 
(see Figure 3). For both females and males, there was generally an 
increase in the number of prescriptions dispensed towards the 
end of the year, and a slight decrease during the winter (June).
The antiobesity products in this study were only available on 
prescription. The majority of the products were Schedule 5 
(92.44%), followed by Schedule 3 (6.08%) and Schedule 6 (1.48%). 
Both Schedule 5 and Schedule 6 products are strictly controlled. 
Schedule 6 products cannot be repeated, and a patient needs a 
new prescription every time they are dispensed.
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2 diabetes, and improves other health consequences of obesity.24 
If lifestyle modifications alone are not effective, there are 
antiobesity preparations available. These agents are not without 
side effects and potential risks. However, if used rationally, 
antiobesity preparations have an important supplementary role 
to play in combatting the emerging obesity epidemic in South 
Africa. More research is needed on the effectiveness of antiobesity 
preparations in South Africa. These studies should ideally be 
conducted by dietitians in conjunction with pharmacists.
Limitations of the study
The study had several limitations. Only prescriptions that were 
dispensed by a group of community pharmacies were included 
in the study, and the study covered only a period of one year. No 
clinical information was available, such as the BMI of patients, 
and diagnoses were also not specific. Appetite suppressants that 
patients can buy over-the-counter and the various herbal 
products that can be used to control weight were also not 
included in the study.
Conclusion
Lifestyle modification is considered to be the first-line therapy 
for obese adult and paediatric patients. Second-line therapy for 
severe obesity is pharmacotherapy. This study investigated the 
dispensing patterns of prescription-only antiobesity preparations 
by community pharmacies. A follow-up study is currently being 
conducted to determine which medication classes were co-
prescribed with antiobesity preparations, especially whether 
patients using antiobesity preparations are also on antidiabetic, 
hypolipidaemic and/or antihypertensive medication. In addition, 
limited information is available on the cost-effectiveness of these 
products in South Africa and also on the long-term outcomes of 
patients who have used these products. These are aspects that 
warrant further investigation.
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